Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 2/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.54 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21890121 | 1.00 | PRCP (0.56) | PRCPOPRM1OPRK1OPRD1OPRL1 | |
| SCHEMBL23057928 | 1.00 | PRCP (0.56) | PRCPOPRM1OPRK1OPRD1OPRL1 | |
| SCHEMBL19020713 | 0.86 | PRCP (0.53) | PRCPOPRM1OPRK1OPRD1OPRL1 | |
| SCHEMBL8011451 | 0.86 | PRCP (0.53) | PRCPOPRM1OPRK1OPRD1OPRL1 | |
| SCHEMBL30952114 | 0.84 | PRCP (0.54) | PRCPOPRM1OPRK1OPRD1OPRL1 | |
| SCHEMBL3245156 | 0.84 | KCNN2 (0.55) | PRCPOPRM1OPRK1OPRD1OPRL1 | |
| SCHEMBL3255532 | 0.84 | PRCP (0.54) | PRCPOPRM1OPRK1OPRD1OPRL1 | |
| SCHEMBL11473332 | 0.84 | PRCP (0.54) | PRCPOPRM1OPRK1OPRD1OPRL1 | |
| SCHEMBL8820261 | 0.83 | OPRM1 (0.50) | PRCPOPRM1OPRK1OPRD1OPRL1 | |
| SCHEMBL3248329 | 0.83 | PRCP (0.53) | PRCPOPRM1OPRK1OPRD1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271938-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CAPELLA THERAPEUTICS, INC. | 2023-08-31 | — | — | US | disclosed |
| WO-2018100045-A1 | ORTHO SUBSTITUTED PHENYLPYRAZOLO- AND PHENYLPYRROLO-PYRIDAZINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2018-06-07 | — | — | WO | disclosed |
| WO-2009095253-A1 | 6-HALO-PYRAZOLO[1, 5-A]PYRIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR (MGLUR) MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271938-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CHKB, CHKA, CHUK | PRCP 2585/4885OPRM1 4451/4885OPRK1 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.